Aurélien Marabelle
#155,649
Most Influential Person Now
Researcher
Aurélien Marabelle's AcademicInfluence.com Rankings
Aurélien Marabelleengineering Degrees
Engineering
#6477
World Rank
#7808
Historical Rank
Cybernetics
#131
World Rank
#137
Historical Rank
Biomedical Engineering
#579
World Rank
#589
Historical Rank
Applied Physics
#2074
World Rank
#2113
Historical Rank
Download Badge
Engineering Physics
Aurélien Marabelle's Degrees
- PhD Biomedical Engineering Université Paris Cité
- Masters Biomedical Engineering Université Paris Cité
- Bachelors Physics Université Paris Cité
Why Is Aurélien Marabelle Influential?
(Suggest an Edit or Addition)Aurélien Marabelle's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Immune-related adverse events with immune checkpoint blockade: a comprehensive review. (2016) (1560)
- Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study. (2020) (1193)
- Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1 (2016) (889)
- Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. (2020) (873)
- Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination (2016) (741)
- Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper. (2016) (710)
- A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study. (2018) (603)
- Elevated Calprotectin and Abnormal Myeloid Cell Subsets Discriminate Severe from Mild COVID-19 (2020) (537)
- Targeting the tumor microenvironment: removing obstruction to anticancer immune responses and immunotherapy. (2016) (523)
- Depleting tumor-specific Tregs at a single site eradicates disseminated tumors. (2013) (328)
- Hyperprogressive disease: recognizing a novel pattern to improve patient management (2018) (277)
- Tocilizumab, an anti-IL-6 receptor antibody, to treat COVID-19-related respiratory failure: a case report (2020) (257)
- Mechanisms and therapeutic implications of hypermutation in gliomas (2020) (256)
- Anti-KIR antibody enhancement of anti-lymphoma activity of natural killer cells as monotherapy and in combination with anti-CD20 antibodies. (2013) (250)
- Rationale for anti-OX40 cancer immunotherapy. (2016) (235)
- Patterns of responses in metastatic NSCLC during PD-1 or PDL-1 inhibitor therapy: Comparison of RECIST 1.1, irRECIST and iRECIST criteria. (2018) (232)
- Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors. (2018) (222)
- Evaluation of Readministration of Immune Checkpoint Inhibitors After Immune-Related Adverse Events in Patients With Cancer. (2019) (214)
- Safety and efficacy of anti-programmed death 1 antibodies in patients with cancer and pre-existing autoimmune or inflammatory disease. (2018) (205)
- Rheumatoid arthritis and polymyalgia rheumatica occurring after immune checkpoint inhibitor treatment (2017) (188)
- Intratumoral immunotherapy: using the tumor as the remedy (2017) (184)
- PARP inhibition enhances tumor cell–intrinsic immunity in ERCC1-deficient non–small cell lung cancer (2019) (183)
- The Potential of Combined Immunotherapy and Antiangiogenesis for the Synergistic Treatment of Advanced NSCLC (2017) (170)
- Intratumoral Immunization: A New Paradigm for Cancer Therapy (2014) (167)
- Predictors of responses to immune checkpoint blockade in advanced melanoma (2017) (162)
- Targeting CD137 enhances the efficacy of cetuximab. (2014) (160)
- Mutational Landscape and Sensitivity to Immune Checkpoint Blockers (2016) (154)
- T-cell–based Immunotherapy: Adoptive Cell Transfer and Checkpoint Inhibition (2015) (149)
- Haematological immune-related adverse events induced by anti-PD-1 or anti-PD-L1 immunotherapy: a descriptive observational study. (2019) (144)
- Biomarkers associated with checkpoint inhibitors. (2016) (141)
- Phase 2 study of pembrolizumab in advanced small-cell lung cancer (SCLC): KEYNOTE-158. (2018) (141)
- Phase I Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) Administered with PD-L1 Inhibitor (Atezolizumab) in Advanced Solid Tumors (2019) (136)
- Prevalence of immune-related systemic adverse events in patients treated with anti-Programmed cell Death 1/anti-Programmed cell Death-Ligand 1 agents: A single-centre pharmacovigilance database analysis. (2017) (135)
- Liver injury from cancer immunotherapy using monoclonal immune checkpoint inhibitors (2018) (131)
- Preliminary results of the first-in-human (FIH) study of MK-1454, an agonist of stimulator of interferon genes (STING), as monotherapy or in combination with pembrolizumab (pembro) in patients with advanced solid tumors or lymphomas. (2018) (126)
- Sustained Type I interferon signaling as a mechanism of resistance to PD-1 blockade (2019) (124)
- Phase Ia and Ib studies of the novel carcinoembryonic antigen (CEA) T-cell bispecific (CEA CD3 TCB) antibody as a single agent and in combination with atezolizumab: Preliminary efficacy and safety in patients with metastatic colorectal cancer (mCRC). (2017) (119)
- Clinical impact of the NKp30/B7-H6 axis in high-risk neuroblastoma patients (2015) (118)
- Starting the fight in the tumor: expert recommendations for the development of human intratumoral immunotherapy (HIT-IT) (2018) (114)
- Infectious complications associated with the use of immune checkpoint inhibitors in oncology: reactivation of tuberculosis after anti PD-1 treatment. (2017) (113)
- Prospective validation of a prognostic score for patients in immunotherapy phase I trials: The Gustave Roussy Immune Score (GRIm-Score). (2017) (112)
- EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors (2020) (112)
- Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications (2015) (111)
- A Phase I Study of the CDK4/6 Inhibitor Ribociclib (LEE011) in Pediatric Patients with Malignant Rhabdoid Tumors, Neuroblastoma, and Other Solid Tumors (2017) (110)
- Pembrolizumab therapy for microsatellite instability high (MSI-H) colorectal cancer (CRC) and non-CRC. (2017) (110)
- Hypermutated tumours in the era of immunotherapy: The paradigm of personalised medicine. (2017) (104)
- Intratumoural administration and tumour tissue targeting of cancer immunotherapies (2021) (104)
- LBA18Efficacy of BMS-986016, a monoclonal antibody that targets lymphocyte activation gene-3 (LAG-3), in combination with nivolumab in pts with melanoma who progressed during prior anti–PD-1/PD-L1 therapy (mel prior IO) in all-comer and biomarker-enriched populations (2017) (103)
- Pattern recognition receptors: immune targets to enhance cancer immunotherapy (2017) (100)
- Can immunostimulatory agents enhance the abscopal effect of radiotherapy? (2016) (98)
- Photopheresis in pediatric graft‐versus‐host disease after allogeneic marrow transplantation: clinical practice guidelines based on field experience and review of the literature (2007) (94)
- Renal toxicities associated with pembrolizumab (2018) (93)
- Turning tumour cells into antigen presenting cells: The next step to improve cancer immunotherapy? (2016) (91)
- Combination strategies to enhance antitumor ADCC. (2012) (91)
- Immune Checkpoint Modulation for Non–Small Cell Lung Cancer (2015) (88)
- 18F-FDG PET and CT Scans Detect New Imaging Patterns of Response and Progression in Patients with Hodgkin Lymphoma Treated by Anti–Programmed Death 1 Immune Checkpoint Inhibitor (2018) (86)
- Immune Checkpoint Blockade, Immunogenic Chemotherapy or IFN-α Blockade Boost the Local and Abscopal Effects of Oncolytic Virotherapy. (2017) (86)
- Challenges of phase 1 clinical trials evaluating immune checkpoint-targeted antibodies. (2016) (86)
- Detection of immune-related adverse events by medical imaging in patients treated with anti-programmed cell death 1. (2018) (85)
- Association of tumour mutational burden with outcomes in patients with select advanced solid tumours treated with pembrolizumab in KEYNOTE-158 (2019) (85)
- The immuno-oncological challenge of COVID-19 (2020) (83)
- Immune responses during COVID-19 infection (2020) (81)
- Mature tertiary lymphoid structures predict immune checkpoint inhibitor efficacy in solid tumors independently of PD-L1 expression (2021) (81)
- Long-Term Survival in Patients Responding to Anti–PD-1/PD-L1 Therapy and Disease Outcome upon Treatment Discontinuation (2018) (79)
- Metabolomic analyses of COVID-19 patients unravel stage-dependent and prognostic biomarkers (2021) (76)
- Prognostic and theranostic 18F-FDG PET biomarkers for anti-PD1 immunotherapy in metastatic melanoma: association with outcome and transcriptomics (2019) (76)
- Pembrolizumab in Patients With Microsatellite Instability–High Advanced Endometrial Cancer: Results From the KEYNOTE-158 Study (2022) (76)
- PD-Loma: a cancer entity with a shared sensitivity to the PD-1/PD-L1 pathway blockade (2018) (72)
- Pembrolizumab for advanced biliary adenocarcinoma: Results from the multicohort, phase II KEYNOTE-158 study. (2018) (71)
- Pembrolizumab for previously treated advanced cervical squamous cell cancer: Preliminary results from the phase 2 KEYNOTE-158 study. (2017) (67)
- Immunodynamics: a cancer immunotherapy trials network review of immune monitoring in immuno-oncology clinical trials (2016) (67)
- Oncolysis without viruses — inducing systemic anticancer immune responses with local therapies (2019) (65)
- Detection of tumor ALK status in neuroblastoma patients using peripheral blood (2015) (65)
- Pembrolizumab treatment of advanced cervical cancer: Updated results from the phase 2 KEYNOTE-158 study. (2018) (65)
- Inflammatory gastrointestinal diseases associated with PD-1 blockade antibodies (2017) (63)
- Targeting immune effector cells to promote antibody-induced cytotoxicity in cancer immunotherapy. (2011) (61)
- Overcoming Resistance to Tumor-Targeted and Immune-Targeted Therapies. (2021) (58)
- Tetraspanin CD81 promotes tumor growth and metastasis by modulating the functions of T regulatory and myeloid-derived suppressor cells. (2015) (56)
- 386PEfficacy of pembrolizumab in phase 2 KEYNOTE-164 and KEYNOTE-158 studies of microsatellite instability high cancers (2017) (56)
- Chemokine receptor patterns in lymphocytes mirror metastatic spreading in melanoma. (2016) (55)
- Worsening and newly diagnosed paraneoplastic syndromes following anti-PD-1 or anti-PD-L1 immunotherapies, a descriptive study (2019) (54)
- Inflammatory gastrointestinal diseases associated with PD-1 blockade antibodies. (2017) (54)
- Rapid and objective CT scan prognostic scoring identifies metastatic patients with long-term clinical benefit on anti-PD-1/-L1 therapy. (2016) (54)
- Tumour burden and efficacy of immune-checkpoint inhibitors (2021) (54)
- Prevalence and Clinical Patterns of Ocular Complications Associated With Anti-PD-1/PD-L1 Anticancer Immunotherapy. (2019) (54)
- Microenvironment-Driven Shift of Cohesion/Detachment Balance within Tumors Induces a Switch toward Metastasis in Neuroblastoma. (2017) (53)
- Intratumoral Anti-CTLA-4 Therapy: Enhancing Efficacy While Avoiding Toxicity (2013) (51)
- Circulating T-cell Immunosenescence in Patients with Advanced Non–small Cell Lung Cancer Treated with Single-agent PD-1/PD-L1 Inhibitors or Platinum-based Chemotherapy (2020) (51)
- Two cases of immune thrombocytopenia associated with pembrolizumab. (2016) (50)
- Abscopal effect in a Hodgkin lymphoma patient treated by an anti-programmed death 1 antibody. (2016) (50)
- The oncolytic peptide LTX-315 overcomes resistance of cancers to immunotherapy with CTLA4 checkpoint blockade (2016) (49)
- Paradigm shift in oncology: targeting the immune system rather than cancer cells. (2015) (49)
- Dose escalation results from a first-in-human, phase 1 study of glucocorticoid-induced TNF receptor–related protein agonist AMG 228 in patients with advanced solid tumors (2018) (49)
- Immune Checkpoint Inhibitor Therapy Aggravates T Cell–Driven Plaque Inflammation in Atherosclerosis (2020) (48)
- TWIST1 is a direct transcriptional target of MYCN and MYC in neuroblastoma. (2015) (46)
- Repurposing rotavirus vaccines for intratumoral immunotherapy can overcome resistance to immune checkpoint blockade (2019) (45)
- Active and passive immunotherapy for lymphoma: proving principles and improving results. (2011) (45)
- Trial watch: Tumor-targeting monoclonal antibodies for oncological indications (2015) (44)
- Prognostic 18F-FDG PET biomarkers in metastatic mucosal and cutaneous melanoma treated with immune checkpoint inhibitors targeting PD-1 and CTLA-4 (2020) (44)
- Immunotherapy discontinuation — how, and when? Data from melanoma as a paradigm (2020) (42)
- NKp30 isoforms and NKp30 ligands are predictive biomarkers of response to imatinib mesylate in metastatic GIST patients (2017) (42)
- Outcomes of long-term responders to anti-programmed death 1 and anti-programmed death ligand 1 when being rechallenged with the same anti-programmed death 1 and anti-programmed death ligand 1 at progression. (2018) (41)
- Impact of aging on immune-related adverse events generated by anti-programmed death (ligand)PD-(L)1 therapies. (2020) (40)
- Cancer vaccines: the next immunotherapy frontier (2022) (38)
- Drug-induced lupus erythematosus following immunotherapy with anti-programmed death-(ligand) 1 (2018) (35)
- Moving Immune Checkpoint Blockade in Thoracic Tumors beyond NSCLC (2016) (34)
- Allogeneic or haploidentical HSCT for refractory or relapsed solid tumors in children: toward a neuroblastoma model (2008) (34)
- CAR-T cells and BiTEs in solid tumors: challenges and perspectives (2021) (33)
- Long-term side effects of radiotherapy for pediatric localized neuroblastoma (2015) (33)
- How to manage patients with corticosteroids in oncology in the era of immunotherapy? (2020) (33)
- Baseline lymphopenia should not be used as exclusion criteria in early clinical trials investigating immune checkpoint blockers (PD-1/PD-L1 inhibitors). (2017) (33)
- Determination of 17q gain in patients with neuroblastoma by analysis of circulating DNA (2011) (32)
- Intratumoral Immunotherapy: From Trial Design to Clinical Practice (2020) (32)
- Safety of treatment with nivolumab after ipilimumab-related meningoradiculitis and bilateral optic neuropathy. (2017) (31)
- Applications of single-cell and bulk RNA sequencing in onco-immunology. (2021) (31)
- Prognostic impact of the expression of NCR1 and NCR3 NK cell receptors and PD-L1 on advanced non-small cell lung cancer (2017) (29)
- NK Cell immunotherapy for high‐risk neuroblastoma relapse after haploidentical HSCT (2012) (28)
- Pembrolizumab in microsatellite instability high cancers: Updated analysis of the phase II KEYNOTE-164 and KEYNOTE-158 studies (2019) (28)
- Kinetics and nadir of responses to immune checkpoint blockade by anti-PD1 in patients with classical Hodgkin lymphoma. (2018) (27)
- Graft-versus-tumour effect in refractory metastatic neuroblastoma (2007) (27)
- Prolonged SARS-CoV-2 RNA virus shedding and lymphopenia are hallmarks of COVID-19 in cancer patients with poor prognosis (2021) (26)
- Pembrolizumab for advanced anal squamous cell carcinoma (ASCC): Results from the multicohort, phase II KEYNOTE-158 study. (2020) (26)
- Immunophenotyping of Stage III Melanoma Reveals Parameters Associated with Patient Prognosis. (2016) (26)
- Pembrolizumab for previously treated advanced anal squamous cell carcinoma: Pooled results from the KEYNOTE-028 and KEYNOTE-158 studies. (2020) (26)
- iRECIST: A clarification of tumour response assessment in the immunotherapy era. (2017) (26)
- Response Criteria for Intratumoral Immunotherapy in Solid Tumors: itRECIST (2020) (24)
- Radiotherapy and toll-like receptor agonists. (2015) (24)
- Dual antibody therapy to harness the innate anti-tumor immune response to enhance antibody targeting of tumors. (2015) (24)
- The 2016-2019 ImmunoTOX assessment board report of collaborative management of immune-related adverse events, an observational clinical study. (2020) (24)
- Pathogen Molecular Pattern Receptor Agonists: Treating Cancer by Mimicking Infection (2019) (24)
- Pembrolizumab in Microsatellite Instability High or Mismatch Repair Deficient Cancers: Updated Analysis from the Phase 2 KEYNOTE-158 Study. (2022) (23)
- Evidence of pseudoprogression in patients treated with PD1/PDL1 antibodies across tumor types (2020) (22)
- Development of ICT01, a first-in-class, anti-BTN3A antibody for activating Vγ9Vδ2 T cell–mediated antitumor immune response (2021) (22)
- JAK Mutations as Escape Mechanisms to Anti-PD-1 Therapy. (2017) (22)
- Anti–CTLA-4 Immunotherapy Does Not Deplete FOXP3+ Regulatory T Cells (Tregs) in Human Cancers—Letter (2018) (21)
- 526O High activity of nivolumab in patients with pathogenic exonucleasic domain POLE (edPOLE) mutated Mismatch Repair proficient (MMRp) advanced tumours (2020) (21)
- Clinical Characteristics and Outcome of Patients with Neuroblastoma Presenting Genomic Amplification of Loci Other than MYCN (2014) (20)
- First-in-human phase I study of immunomodulatory E7046, an antagonist of PGE2-receptor E-type 4 (EP4), in patients with advanced cancers (2020) (20)
- Machine learning defined diagnostic criteria for differentiating pituitary metastasis from autoimmune hypophysitis in patients undergoing immune checkpoint blockade therapy. (2019) (20)
- Immunotherapy phase I trials in patients Older than 70 years with advanced solid tumours. (2018) (19)
- Pembrolizumab in patients with MSI-H advanced endometrial cancer from the KEYNOTE-158 study (2019) (19)
- Have lessons from past failures brought us closer to the success of immunotherapy in metastatic pancreatic cancer? (2015) (19)
- Safety and clinical activity of intratumoral MEDI9197 alone and in combination with durvalumab and/or palliative radiation therapy in patients with advanced solid tumors (2020) (19)
- The oncolytic compound LTX-401 targets the Golgi apparatus (2016) (19)
- Plasma proteomics identifies Leukemia Inhibitory Factor (LIF) as a novel predictive biomarker of immune-checkpoint blockade resistance. (2021) (19)
- Stromal lymphocyte infiltration is associated with tumour invasion depth but is not prognostic in high-grade T1 bladder cancer. (2019) (19)
- Design and conduct of early clinical studies of immunotherapy agent combinations: recommendations from the task force on Methodology for the Development of Innovative Cancer Therapies (2018) (18)
- Stability of ipilimumab in its original vial after opening allows its use for at least 4 weeks and facilitates pooling of residues. (2016) (18)
- CD34+ immunoselection of autologous grafts for the treatment of high‐risk neuroblastoma (2011) (18)
- Challenges and perspectives in the immunotherapy of Hodgkin lymphoma. (2017) (18)
- Repurposing infectious disease vaccines for intratumoral immunotherapy (2020) (17)
- In Vitro and In Vivo Comparison of Lymphocytes Transduced with a Human CD16 or with a Chimeric Antigen Receptor Reveals Potential Off-Target Interactions due to the IgG2 CH2-CH3 CAR-Spacer (2015) (17)
- Pembrolizumab for previously treated advanced anal squamous cell carcinoma: results from the non-randomised, multicohort, multicentre, phase 2 KEYNOTE-158 study. (2022) (17)
- Focal nodular hyperplasia of the liver in patients previously treated for pediatric neoplastic diseases. (2008) (17)
- Human epidermal receptor family inhibitors in patients with ERBB3 mutated cancers: Entering the back door. (2018) (16)
- The determinants of very severe immune-related adverse events associated with immune checkpoint inhibitors: A prospective study of the French REISAMIC registry. (2021) (16)
- Fever reaction and haemophagocytic syndrome induced by immune checkpoint inhibitors. (2018) (16)
- Current strategies for intratumoural immunotherapy - Beyond immune checkpoint inhibition. (2021) (16)
- 403PPhase I studies of the novel carcinoembryonic antigen T-cell bispecific (CEA-CD3 TCB) antibody as a single agent and in combination with atezolizumab: Preliminary efficacy and safety in patients (pts) with metastatic colorectal cancer (mCRC) (2017) (15)
- Pattern recognition receptors: immune targets to enhance cancer immunotherapy. (2019) (15)
- Abstract CT150: A first-in-human phase I study of the OX40 agonist GSK3174998 (GSK998) +/- pembrolizumab in patients (Pts) with selected advanced solid tumors (ENGAGE-1) (2020) (15)
- Safety, Antitumor Activity, and T-cell Responses in a Dose-Ranging Phase I Trial of the Oncolytic Peptide LTX-315 in Patients with Solid Tumors (2021) (14)
- Tumor‐targeted and immune‐targeted monoclonal antibodies: Going from passive to active immunotherapy (2015) (14)
- Hypercalcemia and 13‐cis‐retinoic acid in post‐consolidation therapy of neuroblastoma (2009) (14)
- Novel carcinoembryonic antigen T-cell bispecific (CEA-TCB) antibody: Preliminary clinical data as a single agent and in combination with atezolizumab in patients with metastatic colorectal cancer (mCRC). (2017) (13)
- Interventional Radiology for Local Immunotherapy in Oncology (2021) (13)
- Melanoma and immunotherapy bridge 2015 (2016) (13)
- SARS-CoV-2 vaccines for cancer patients treated with immunotherapies: Recommendations from the French society for ImmunoTherapy of Cancer (FITC) (2021) (13)
- T cell Bispecific Antibodies in Node-Positive Breast Cancer: Novel Therapeutic Avenue for MHC class I Loss Variants. (2019) (13)
- Abstract CT091: Safety and pharmacodynamic activity of MEDI9197, a TLR 7/8 agonist, administered intratumorally in subjects with solid tumors (2017) (13)
- 455PPHASE I STUDY OF LEE011 (CDK4/6 INHIBITOR) IN PATIENTS WITH MALIGNANT RHABDOID TUMORS, NEUROBLASTOMA, AND CYCLIN D-CDK4/6 PATHWAY-ACTIVATED TUMORS. (2014) (12)
- Reply to: "Incidence of grade 3-4 liver injury under immune checkpoints inhibitors: A retrospective study". (2018) (12)
- Chemotherapy beyond immune checkpoint inhibitors in patients with metastatic colorectal cancer. (2020) (12)
- LBA-004Novel carcinoembryonic antigen T-cell bispecific (CEA-TCB) antibody: Preliminary clinical data as a single agent and in combination with atezolizumab in patients with metastatic colorectal cancer (mCRC). (2017) (12)
- Managing Hyperprogressive Disease in the Era of Programmed Cell Death Protein 1/Programmed Death-Ligand 1 Blockade: A Case Discussion and Review of the Literature. (2020) (12)
- 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two (2016) (11)
- Prime time for immune-checkpoint targeted therapy at ASCO 2015 (2016) (11)
- P315 Gastrointestinal immune related adverse events associated with programmed-Death 1 blockade. (2017) (11)
- Tetraspanin CD81, a modulator of immune suppression in cancer and metastasis (2016) (11)
- Dose escalation results from a first-in-human, phase 1 study of the glucocorticoid-induced TNF receptor-related protein (GITR) agonist AMG 228 in patients (Pts) with advanced solid tumors. (2017) (11)
- Pickering emulsions with ethiodized oil and nanoparticles for slow release of intratumoral anti-CTLA4 immune checkpoint antibodies (2020) (11)
- Upcoming innovations in lung cancer immunotherapy: focus on immune checkpoint inhibitors. (2015) (10)
- Hyperprogression during immunotherapy: do we really want to know? (2019) (10)
- Safety and tolerability of MEDI0562 in combination with durvalumab or tremelimumab in patients with advanced solid tumors. (2020) (10)
- Efficacy of histology-agnostic and molecularly-driven HER2 inhibitors for refractory cancers (2018) (10)
- Patterns of progression in patients treated for immuno-oncology antibodies combination (2020) (10)
- 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one (2016) (10)
- Safety, pharmacokinetics, efficacy, and preliminary biomarker data of first-in-class BI 765063, a selective SIRPα inhibitor: Results of monotherapy dose escalation in phase 1 study in patients with advanced solid tumors. (2021) (10)
- PD-1 blockade in solid tumors with defects in polymerase epsilon. (2022) (10)
- Remitting Seronegative Symmetric Synovitis With Pitting Edema Associated With Partial Melanoma Response Under Anti–CTLA‐4 and Anti–Programmed Death 1 Combination Treatment (2018) (10)
- Chemokine biology on immune checkpoint-targeted therapies. (2020) (10)
- [PD-L1 expression: An emerging biomarker in non-small cell lung cancer]. (2016) (9)
- Immune checkpoint inhibitor-based combinations: is dose escalation mandatory for phase I trials? (2019) (9)
- Neurological complications induced by immune checkpoint inhibitors: a comprehensive descriptive case-series unravelling high risk of long-term sequelae (2021) (9)
- Hemophagocytic syndrome revealing primary HHV-6 infection. (2010) (9)
- New insights into the mechanism of action of immune checkpoint antibodies (2014) (9)
- Hyperprogression during immunotherapy: do we really want to know? (2019) (9)
- SO-8 Health-related quality of life in patients treated with pembrolizumab for microsatellite instability-high/mismatch repair deficient advanced solid tumors: Results from the KEYNOTE-158 study (2021) (8)
- Immune checkpoint-targeted antibodies: a room for dose and schedule optimization? (2022) (8)
- Applicability of the lung immune prognostic index (LIPI) in patients with metastatic solid tumors when treated with immune checkpoint inhibitors (ICI) in early clinical trials. (2019) (8)
- A phase I/II study of the oncolytic peptide LTX-315 combined with checkpoint inhibition generates de novo T-cell responses and clinical benefit in patients with advanced solid tumors. (2018) (8)
- Outcomes of patients with cancer and sarcoid-like granulomatosis associated with immune checkpoint inhibitors: A case-control study. (2021) (8)
- Impact of acetaminophen on the efficacy of immunotherapy in cancer patients. (2022) (7)
- Anti-CSF-1R emactuzumab in combination with anti-PD-L1 atezolizumab in advanced solid tumor patients naïve or experienced for immune checkpoint blockade (2022) (7)
- IMMUNOBIOLOGY Anti-KIR antibody enhancement of anti-lymphoma activity of natural killer cells as monotherapy and in combination with anti-CD 20 antibodies (2014) (7)
- CD8+PD-1+ to CD4+PD-1+ ratio (PERLS) is associated with prognosis of patients with advanced NSCLC treated with PD-(L)1 blockers (2022) (7)
- Association between immune-related adverse events and efficacy in patients treated with anti-PD-(L)1. (2018) (7)
- [What's next in glioblastoma treatment: Tumor-targeted or immune-targeted therapies?]. (2016) (7)
- Nivolumab in metastatic nonclear cell renal cell carcinoma: First results of the AcSe prospective study. (2020) (7)
- Incidence of immune related adverse events in patients 70 years old treated with anti-PD-(L)1 therapy. (2018) (7)
- High levels of TNFα in patients with COVID-19 refractory to tocilizumab (2021) (6)
- Stability of nivolumab in its original vials after opening and handing in normal saline bag for intravenous infusion. (2020) (6)
- Safety, recommended dose, efficacy and immune correlates for nintedanib in combination with pembrolizumab in patients with advanced cancers (2022) (6)
- Immuno-Oncology in Cancer Care is a Fantastic Opportunity for Interventional Oncology: IO4IO (Interventional Oncology for Immuno-Oncology) Initiative (2018) (6)
- Gastrointestinal Immune Related Adverse Events Associated with Programmed-Death 1 Blockade (2017) (6)
- Hair Repigmentation With Anti-PD-1 and Anti-PD-L1 Immunotherapy: A Novel Hypothesis. (2018) (6)
- Immunobiology. Combined targeted and immunotherapy: the future of personalized medicine. (2012) (6)
- How should we use anti-CTLA-4 antibodies? (2015) (6)
- Immunodynamics of explanted human tumors for immuno‐oncology (2020) (6)
- Absence of significant clinical benefit for a systematic routine creatine phosphokinase measurement in asymptomatic patients treated with anti-programmed death protein (ligand) 1 immune checkpoint inhibitor to screen cardiac or neuromuscular immune-related toxicities. (2021) (6)
- The Polarity and Specificity of Antiviral T Lymphocyte Responses Determine Susceptibility to SARS-CoV-2 Infection in Patients with Cancer and Healthy Individuals (2022) (6)
- CXCL13 shapes tertiary lymphoid structures and promotes response to immunotherapy in bladder cancer. (2021) (6)
- Artificial intelligence and radiomics: fundamentals, applications, and challenges in immunotherapy (2022) (5)
- Erratum: Depleting tumor-specific Tregs at a single site eradicates disseminated tumors (Journal of Clinical Investigation (2013) 123:11 (4980) DOI:10.1172/JCI73340) (2013) (5)
- Allergic broncho-pulmonary aspergillosis following treatment with an anti-programmed cell death protein 1 monoclonal antibody therapy. (2017) (5)
- Clear cell ependymoma with trisomy 19 developing bone metastases (2012) (5)
- LTX-315, an oncolytic peptide, to convert immunogenically ‘cold' tumors to ‘hot' in patients with advanced or metastatic tumours: Results from an ongoing phase I study. (2017) (5)
- Clinical efficacy of HER3 partners' inhibitors in ERBB3 mutated cancer patients (2016) (5)
- Prevalence and clinical patterns of ocular complications associated with anti PD‐1/PDL‐1 anticancer immunotherapy (2018) (5)
- Safety and efficacy results from a phase I dose-escalation trial of Nintedanib in combination with Pembrolizumab in patients with advanced solid tumors (PEMBIB trial). (2018) (5)
- Escherichia coli-specific CXCL13-producing TFH are associated with clinical efficacy of neoadjuvant PD-1 blockade against muscle-invasive bladder cancer. (2022) (5)
- Organisational factors influencing early clinical trials enrollment: Gustave Roussy experience. (2018) (4)
- Analysis of the association between prospectively collected immune-related adverse events and survival in patients with solid tumor treated with immune-checkpoint blockers, taking into account immortal-time bias. (2022) (4)
- CD8+ T Lymphocytes Immune Depletion and LAG-3 Overexpression in Hodgkin Lymphoma Tumor Microenvironment Exposed to Anti-PD-1 Immunotherapy (2021) (4)
- 291 Phase Ib study of selicrelumab (CD40 agonist) in combination with atezolizumab (anti-PD-L1) in patients with advanced solid tumors (2020) (4)
- Foxp3+ cells are running the show in patients with surgically resected nonsmall cell lung cancer (2015) (4)
- Immunosenescence, inflammaging, and cancer immunotherapy efficacy (2022) (4)
- 1164PPatterns of progression under antiPD1/PDL1 in advanced NSCLC patients allow discriminating pseudo-progression from real progression (2017) (4)
- P1.01-07 Immune-Related Pneumonitis in NSCLC Patients Treated with Immune Checkpoint Inhibitors (ICI): Impact of Previous Thoracic Radiotherapy (2018) (4)
- 3OApplicability of the lung immune prognostic index (LIPI) in patients with metastatic solid tumors when treated with immune checkpoint inhibitors (ICI) in early clinical trials. (2019) (4)
- BCG therapy downregulates HLA-I on malignant cells to subvert antitumor immune responses in bladder cancer (2022) (4)
- Primary results of STRONG: An open-label, multicenter, phase 3b study of fixed-dose durvalumab monotherapy in previously treated patients with urinary tract carcinoma (2022) (4)
- Late-occurring nivolumab-induced cryptogenic organising pneumonia mimicking lung progression in a patient with metastatic non-small cell lung cancer. (2017) (4)
- Pegylated Engineered IL2 plus Anti-PD-1 Monoclonal Antibody: The Nectar Comes from the Combination. (2020) (4)
- 983P Phase I dose escalation study in patients (pts) with advanced solid tumours receiving first-in-class BI 765063, a selective signal-regulatory protein α (SIRPα) inhibitor, in combination with ezabenlimab (BI 754091), a programmed cell death protein 1 (PD-1) inhibitor (2021) (4)
- Circulating L-Arginine predicts the survival of cancer patients treated with immune checkpoint inhibitors. (2022) (4)
- High level of activity of nivolumab anti-PD-1 immunotherapy and favorable outcome in metastatic/refractory MSI-H non-colorectal cancer: Results of the MSI cohort from the French AcSé program (2019) (4)
- Feasibility, safety and efficacy of human intra-tumoral immuno-therapy. Gustave Roussy's initial experience with its first 100 patients. (2022) (4)
- 795MO Pembrolizumab (pembro) in patients (pts) with microsatellite instability-high (MSI-H) advanced endometrial cancer (EC): Updated results from KEYNOTE-158 (2021) (4)
- Identification of new prognostic factors in phase I patients treated by immunotherapy (2016) (4)
- Treatment with a retinoic acid-inducible gene I (RIG-I) agonist as monotherapy and in combination with pembrolizumab in patients with advanced solid tumors: results from two phase 1 studies (2022) (3)
- Pembrolizumab in microsatellite instability high (MSI-H)/mismatch repair deficient (dMMR) cancers: Updated analysis from phase 2 KEYNOTE-158 study. (2021) (3)
- A Phase 1 Study Evaluating BI 765063, a First in Class Selective Myeloid Sirpa Inhibitor, As Stand-Alone and in Combination with BI 754091, a Programmed Death-1 (PD-1) Inhibitor, in Patients with Advanced Solid Tumours (2019) (3)
- Immunomodulatory antibodies for the treatment of lymphoma: Report on the CALYM Workshop (2016) (3)
- ASSOCIATION OF LIPI SCORE WITH IMMUNOTHERAPY OUTCOMES IN ELDERLY POPULATION (2019) (3)
- Design and Conduct of Early Clinical Studies of Immunotherapy: Recommendations from the Task Force on Methodology for the Development of Innovative Cancer Therapies 2019 (MDICT) (2020) (3)
- OP0165 EULAR RECOMMENDATIONS FOR THE DIAGNOSIS AND THE MANAGEMENT OF RHEUMATIC IMMUNE-RELATED ADVERSE EVENTS DUE TO CANCER IMMUNOTHERAPY (2019) (3)
- High serum LDH and liver metastases are the dominant predictors of primary cancer resistance to anti-PD(L)1 immunotherapy. (2022) (3)
- 316 EVICTION Study: Preliminary results in solid tumor patients with ICT01, a first-in-class, gamma9 delta2 T cell activating antibody targeting butyrophilin-3A (2020) (3)
- Basket trial health technology assessment requirements and limited access to innovations in oncology: The French paradox. (2022) (3)
- Overcoming resistance to αPD-1 of MMR-deficient tumors with high tumor-induced neutrophils levels by combination of αCTLA-4 and αPD-1 blockers (2022) (3)
- Delivering adapted physical activity by videoconference to patients with fatigue under immune checkpoint inhibitors: Lessons learned from the PACTIMe-FEAS feasibility study. (2021) (3)
- Abstract CT034: Activation of the antitumor immune response of gamma9delta2 T cells in patients with solid or hematologic malignancies with ICT01, a first-in-class, monoclonal antibody targeting butyrophilin 3A: The EVICTION study (2021) (2)
- A phase 1 study to evaluate the safety, pharmacokinetics, pharmacodynamics, immunogenicity, and antitumor activity of the OX40 agonist MEDI0562 in combination with tremelimumab or durvalumab in adult aubjects with advanced solid tumors. (2017) (2)
- 277 Safety and efficacy of intratumoral ipilimumab with IV nivolumab in metastatic melanoma. The NIVIPIT trial (2021) (2)
- The ImmunoTOX multidisciplinary board: A descriptive study of collaborative management of immune-related adverse events (2019) (2)
- Health-related quality of life with pembrolizumab monotherapy in patients with previously treated advanced microsatellite instability high/mismatch repair deficient endometrial cancer in the KEYNOTE-158 study. (2022) (2)
- Reply to: "Immune-related hepatitis with immunotherapy: Are corticosteroids always needed?" (2018) (2)
- Tumour mutational burden in treatment-resistant tumours - Authors' reply. (2020) (2)
- PV-0208 Immune-related pneumonitis in NSCLC patients treated with ICI: impact of previous thoracic RT (2019) (2)
- 715P Nivolumab in pretreated metastatic penile squamous cell carcinoma: Results of the penile cohort from the French AcSé prospective program (2021) (2)
- Sarcoidosis-like reaction mimics progression in patients treated with immune checkpoint inhibitors (2019) (2)
- Pembrolizumab in combination with bevacizumab and pegylated liposomal doxorubicin in patients with platinum-resistant epithelial ovarian cancer. (2021) (2)
- Protective effect of obesity on survival in cancers treated with immunotherapy vanishes when controlling for type of cancer, weight loss and reduced skeletal muscle. (2022) (2)
- [From Ipex to foxp3: a new contribution of pediatrics to the understanding of the immune system]. (2008) (2)
- Cabergoline therapy of paraneoplastic cushing syndrome in children (2010) (2)
- 34MO Outcomes according to FGFR alteration types in patients with a solid tumour treated by a pan-FGRF tyrosine kinase inhibitor in phase I/II trials (2021) (2)
- Case Report: Response to Immunotherapy, Can Radiotherapy Be a Troublemaker? (2021) (2)
- RBD- specific Th1 responses are associated with vaccine-induced protection against SARS-CoV-2 infection in patients with hematological malignancies (2023) (2)
- Phase I study of E7046, a novel PGE2 receptor type 4 inhibitor, in patients with advanced solid tumors: Clinical results and effects on myeloid- and T-lymphoid cell-mediated immunosuppression. (2018) (2)
- PD-Loma: a cancer entity with a shared sensitivity to the PD-1/PD-L1 pathway blockade (2018) (2)
- Health-related quality of life in patients treated with pembrolizumab for microsatellite instability-high/mismatch repair-deficient advanced solid tumours: Results from the KEYNOTE-158 study. (2022) (2)
- 104PPharmacokinetics (PK) and pharmacodynamics (PD) of a novel carcinoembryonic antigen (CEA) T-cell bispecific antibody (CEA-CD3 TCB) for the treatment of CEA-positive solid tumors (2017) (2)
- Neuropilin-1 cooperates with PD-1 in CD8+ T cells predicting outcomes in melanoma patients treated with anti-PD1 (2022) (2)
- Targeting CD137 enhances the efficacy of cetuximab. (2019) (2)
- The oncolytic compound LTX-401 targets the Golgi apparatus (2017) (2)
- Immune checkpoint inhibitor-based combinations: is dose escalation mandatory for phase 1 trials? (2019) (2)
- 794 Safety and efficacy results from a phase 1/1b study of intratumoral MK-4621, a retinoic acid-inducible gene I (RIG-I) agonist, plus intravenous pembrolizumab in patients with advanced solid tumors (2020) (2)
- OP0004 Rheumatoid arthritis occuring after immune checkpoint inhibitors (2017) (2)
- EULAR recommendations for the diagnosis and the management of rheumatic immune-related adverse events due to cancer immunotherapy (2019) (2)
- Pattern recognition receptors: immune targets to enhance cancer immunotherapy. (2019) (2)
- In Vitro and In Vivo Comparison of Lymphocytes Transduced with a Human CD 16 or with a Chimeric Antigen Receptor Reveals Potential Off-Target Interactions due to the IgG 2 CH 2CH 3 CAR-Spacer (2015) (2)
- Association of stromal lymphocyte infiltration with tumor invasion depth and high-grade T1 bladder cancer. (2018) (2)
- Reply to: "Acute liver failure due to immune-mediated hepatitis successfully managed with plasma exchange: New settings call for new treatment strategies?" (2019) (2)
- Paradoxical cancer cell stimulation by IFNγ drives tumor hyperprogression upon checkpoint blockade immunotherapy. (2023) (1)
- CTIM-03. PEMBROLIZUMAB MONOTHERAPY FOR MICROSATELLITE INSTABILITY-HIGH (MSI-H) OR MISMATCH REPAIR DEFICIENT (DMMR) RECURRENT GLIOMAS: RESULTS FROM THE MULTICOHORT PHASE 2 KEYNOTE-158 STUDY (2022) (1)
- Immune-related adverse events (irAEs) and outcome in recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) patients (pts) treated by immune-checkpoints inhibitors (ICI) (2019) (1)
- Thromboembolic risk assessment in patients receiving combination of anti-angiogenic plus anti-PD1 or anti-PD-L1: A descriptive study (2019) (1)
- Multiple immune-related toxicities in cancer patients treated with anti-programmed death 1 immunotherapies: a new surrogate marker for clinical trials? (2021) (1)
- Sequential tumor and dual immune targeted immunotherapy: anti-lymphoma activity of Rituximab with 4-1bb stimulation and PD-1 blockade (2014) (1)
- Pharmacokinetics (PK) and pharmacodynamics (PD) of a novel carcinoembryonic antigen (CEA) T-cell bispecific antibody (CEA CD3 TCB) for the treatment of CEA-expressing solid tumors. (2017) (1)
- Abstract 4563: Local and abscopal effects in oncolytic virotherapy are boosted by immune checkpoint blockade, immunogenic chemotherapy, or IFNAR blockade (2017) (1)
- Erratum: The oncolytic compound LTX-401 targets the Golgi apparatus. (2018) (1)
- Molecular alterations and matched treatment in older patients: Results from the MOSCATO 01 trial. (2018) (1)
- MA05.11 Safety and Efficacy of Nintedanib in Combination with Pembrolizumab in Patients with Refractory/Relapsing Malignant Pleural Mesothelioma (2019) (1)
- 508P High prevalence of clonal hematopoiesis of indeterminate potential (CHIP) associated mutations in elderly patients with solid tumors (2022) (1)
- 1294P 18F-FDG PET-TC derived parameters as a tool to select pembrolizumab single agent or in combination with chemotherapy in first-line NSCLC (2021) (1)
- Predicting Immunotherapy Outcomes in Older Patients with Solid Tumors Using the LIPI Score (2022) (1)
- Sustained cancer clinical trial activity in a French hospital during the first wave of the COVID-19 pandemic (2021) (1)
- 22P Toxicity profile of immune and non-immune therapies in phase I/II trials: A comprehensive longitudinal analysis (2021) (1)
- Identification of super-exhausted T cells: A novel population predictive of response to immunotherapy. (2022) (1)
- Defining the Role of a Novel Immune Checkpoint Modulator: Anti-OX40 (2015) (1)
- Hyperprogression upon immunotherapy: A chance for (hyper-)progress. (2020) (1)
- Safety and tolerability of MEDI0562, an OX40 agonist monoclonal antibody, in combination with durvalumab or tremelimumab in adult patients with advanced solid tumors. (2022) (1)
- Rationale for LDH-targeted cancer immunotherapy. (2022) (1)
- A tribute to the life and career of Holbrook Kohrt. (2016) (1)
- How do immune checkpoint-targeted antibodies work? The need for improved pharmacokinetic evaluation in early phase studies. (2018) (1)
- A phase I dose escalation trial evaluating the impact of an in situ immunization strategy with intra-tumoral injections of Pexa-Vec in combination with ipilimumab in advanced solid tumors with injectable lesions (2018) (1)
- 355 Pembrolizumab and bevacizumab in platinum resistant epithelial ovarian cancer patients (2021) (1)
- Phase 1 study of E7046, an inhibitor of the PGE2 receptor EP-4, that targets immunosuppressive myeloid cells in the tumor microenvironment (NCT02540291). (2016) (1)
- Synergizing liver systemic treatments with interventional oncology: friend or foe? (2022) (1)
- OS9.1 Clinical significance of hypermutation in gliomas (2019) (1)
- Predictive markers of immune mediated adverse events and of treatment response in patients treated with durvalumab monotherapy or in combination with tremelimumab (IOPREDI study) (2018) (1)
- Safety and efficacy of nivolumab, an anti-PD1 immunotherapy, in patients with advanced basal cell carcinoma, after failure or intolerance to sonic Hedgehog inhibitors: UNICANCER AcSé NIVOLUMAB trial. (2022) (1)
- 970P MEDINDUCTION: Phase I trial evaluating the safety of durvalumab in combination with docetaxel, cisplatin and 5-FU (DCF) as induction therapy for locally advanced squamous cell carcinoma of the head and neck (SCCHN) (2020) (1)
- A microsimulation model to assess the economic impact of immunotherapy in non-small cell lung cancer (2020) (1)
- Single-cell transcriptomics reveals shared immunosuppressive landscapes of mouse and human neuroblastoma (2022) (1)
- Epigenetic gene alterations in metastatic solid tumours: results from the prospective precision medicine MOSCATO and MATCH-R trials. (2022) (1)
- 1801MO Neutrophils are associated with resistance to anti-PD-1 monotherapy in mismatch repair-deficient tumors (2021) (1)
- 807 A multicenter open-label phase I/lb study of SO-C101 as monotherapy and in combination with pembrolizumab in patients with selected advanced/metastatic solid tumors (2020) (1)
- [Toxicities of immune checkpoint inhibitors and their management]. (2019) (1)
- Immune contexture of paediatric cancers. (2022) (1)
- Genomic Instability and Protumoral Inflammation Are Associated with Primary Resistance to Anti–PD-1 + Antiangiogenesis in Malignant Pleural Mesothelioma (2023) (1)
- Mechanisms and therapeutic implications of hypermutation in gliomas (2020) (1)
- Abstract 2466: Sequential tumor and immune targeted immunotherapy: Anti-tumor activity of antibody drug conjugate Trastuzumab Emtansine (T-DM1) with CD137 stimulation in HER-2+ breast cancer therapy (2015) (0)
- 546P Pembrolizumab for microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) advanced endometrial cancer: Long-term follow-up results from KEYNOTE-158 (2022) (0)
- 716 AURELIO-04: a phase 2, open-label, single-arm, multicenter study to determine the efficacy and safety of SOT101 in combination with pembrolizumab in patients with selected advanced solid tumors (2022) (0)
- Response criteria for intratumoral immunotherapy in solid tumors: ItRECIST. (2020) (0)
- Immunotherapy advances in cancers with mismatch repair or proofreading deficiencies. (2022) (0)
- 1165P Immune checkpoint inhibitors following targeted therapies in MITF family translocation renal cell carcinomas (2017) (0)
- Safety assessment of anti-PD(L)1 rechallenge after immune-related adverse events. (2018) (0)
- Abstract CT188: ICT01, an anti-butyrophilin 3A targeted mAb activating g9d2 T cells, induces immune remodeling of the tumor microenvironment and clinical responses in combination with pembrolizumab in patients with advanced solid tumors who failed prior checkpoint inhibitor therapy: EVICTION Trial (2022) (0)
- An open-label, multicenter, phase IIIb study of patients with urinary tract carcinoma (UTC) (STRONG): Final analysis for fixed-dose durvalumab monotherapy (module A). (2021) (0)
- Introduction to Pediatric Cancer Immunotherapy (2018) (0)
- Interim safety and efficacy results from AURELIO-03: A phase 1 dose escalation study of the IL-2/IL-15 receptor βγ superagonist SOT101 as a single agent and in combination with pembrolizumab in patients with advanced solid tumors. (2022) (0)
- 1282P Biology of immune resistance in oncogenic driven advanced non-small cell lung cancer (aNSCLC) (2021) (0)
- 484 Preliminary efficacy of the IL-15 superagonist SO-C101 in combination with pembrolizumab in patients with advanced/metastatic solid tumors (2021) (0)
- Abstract LB-253: A comprehensive evaluation of immune checkpoints ligands (ICPLs) in more than 1,000 cancer cell lines (CCLs) identifies specific expression patterns (2014) (0)
- 162TiP A phase I study evaluating BI 765063, a first in class selective myeloid SIRPa inhibitor, as standalone and in combination with BI 754091, a programmed death-1 (PD-1) inhibitor, in patients with advanced solid tumours (2019) (0)
- 1163PImmunotherapy phase I trials in patients over 70 years with advanced solid tumours: The Gustave Roussy experience (2017) (0)
- 461P Overview of patients inclusions and outcomes into modern phase I trials at Gustave Roussy over the last 5 years, OVATION study (2022) (0)
- O2.5Novel immunostimulatory antibodies: What's next? (2015) (0)
- Better than RECIST and faster than iRECIST: defining the Immunotherapy Progression Decision score to better manage progressive tumors on immunotherapy. (2022) (0)
- Cancer immunotherapy efficacy is driven by tumour biology, not by its histology. Impact on drug development and approvals. (2022) (0)
- [Impact of the use of systemic corticosteroid therapy on the effectiveness of immune checkpoint inhibitors]. (2021) (0)
- Abstract CT021: PD-1 blockade in solid tumors with defects in polymerase epsilon (2022) (0)
- Overall survival prognosis of patients in immuno-oncology phase I trials: The Gustave Roussy score. (2017) (0)
- Intratumoral Immunotherapy: Is It Ready for Prime Time? (2023) (0)
- 1030TiP An open-label multicenter phase Ib study of AN0025, a selective inhibitor of the prostaglandin E2 receptor-type-4 receptor, in combination with pembrolizumab in patients with advanced solid tumors (2021) (0)
- 1159PLong term survival in patients responding to an Anti-PD-1/PD-L1 therapy and disease outcome upon treatment discontinuation (2017) (0)
- 1703PDLandscape of DNA damage response (DDR) genes alterations in the prospective MOSCATO and MATCH R trials (2017) (0)
- Abstract IA25: Local immunomodulation at a single site of tumor generates a therapeutic immune response that cures metastatic disease at distant sites, including the brain. (2013) (0)
- 3 1 . 1 Immune Checkpoints (2018) (0)
- Tumor-Targeted Antibodies (2018) (0)
- 86P Validation of the Gustave Roussy Immune (GRIm) score in patients treated with bispecific CD3 T cell engagers in phase I clinical trials (2023) (0)
- PemBOv trial: Pembrolizumab plus bevacizumab with or without pegylated liposomal doxorubicin-based chemotherapy in patients with platinum-resistant ovarian cancer. (2022) (0)
- Patterns of progression to immune checkpoint targeted monoclonal antibodies in phase I trials. (2018) (0)
- Medical image computing to assess tumor infiltrating CD8 T cells, tumor immune phenotype and response to anti-PD-1/PD-L1 immunotherapy in prospective phase 1 trials. (2018) (0)
- LTX‐315, an oncolytic peptide converts "cold" tumors to "hot" in a majority of patients with advanced cancer: results from an ongoing phase I study (2017) (0)
- Abstract 66: BCG can subvert patients antitumor immune response by downregulating HLA-I expression on cancer cells (2021) (0)
- 284 Integrated molecular characterization of primary resistance mechanisms to immune checkpoint blockade in advanced non-small cell lung carcinoma (a-NSCLC) (2021) (0)
- SP0018 Controling the balance between cancer and autoimmunity (2017) (0)
- Reply to: "Mortality due to immunotherapy related hepatitis". (2018) (0)
- Patients with metastatic prostate cancer enrolled in phase 1 trials: Outcomes and molecular alterations (2016) (0)
- First-in-human phase I study of the OX40 agonist GSK3174998 with or without pembrolizumab in patients with selected advanced solid tumors (ENGAGE-1) (2023) (0)
- Overcoming therapeutic MAb resistance in agressive HER2 positive breast carcinomas by adoptive immunotherapy using optizimed effectors cells (2013) (0)
- 4OPhase 1 study of E7046, a PGE2 receptor EP-4 inhibitor that targets immunosuppressive myeloid cells in the tumor microenvironment (TME) (2017) (0)
- 1070P Previous viral infections assessed by pan-virus phage immunoprecipitation sequencing (PhIP-Seq) predict response to immune checkpoint blockers (ICBs) in non-small cell lung cancer (NSCLC) (2022) (0)
- Targeting Tumor Specific Regulatory T-cells for Cancer Therapy (2013) (0)
- 1617P Sustained cancer clinical trial activity during the COVID-19 pandemic (2021) (0)
- 11P Senescent immune phenotype (SIP) status that predicts resistance to immune checkpoint blockers (ICB) among CMV+ advanced non-small cell lung cancer (aNSCLC) patients is not associated with chronic type I IFN signature (2021) (0)
- Safety and efficacy of the anti-PD1 immunotherapy with nivolumab in trichoblastic carcinomas. (2023) (0)
- Abstract 3112: Prospective immune phenotyping of neuroblastoma children at diagnosis reveals specific immune defects related to the aggressiveness of the disease (2019) (0)
- 1050P Does immunotherapy impact the outcomes of future anti-tumour therapies? (2020) (0)
- Abstract CT040: SOT101, an IL-2/IL-15 Rβγ superagonist, in combination with pembrolizumab in patients with advanced solid tumors: Interim safety and efficacy results from the AURELIO-03 dose escalation trial (2022) (0)
- 1661MO Genomic somatic copy number alterations drive adaptive tumor immune suppression and primary resistance to anti-PD1 + anti-angiogenics in pleural mesothelioma (2022) (0)
- 544 Companion diagnostic assays for pembrolizumab in patients with MSI-H/dMMR tumors (2022) (0)
- Real-world data on antiviral treatments for hepatitis C virus infections: Can we define intention to treat or per protocol analyses? (2018) (0)
- Precision medicine for patients with primary brain tumours: Molecular screening for cancer treatment optimization (MOSCATO) prospective trial (2019) (0)
- Is anti-PD-1/PD-L1 immunotherapy sensitizing for conventional cancer therapies? (2016) (0)
- Safety, recommended dose, efficacy and immune correlates for nintedanib in combination with pembrolizumab in patients with advanced cancers (2022) (0)
- Abstract A051: Prediction of clinical outcomes of cancer patients treated with anti-PD-1/PD-L1 using a radiomics-based imaging score of immune infiltrate (2018) (0)
- AcSé immunotherapy trials: Anti-PD-1 therapy for adult patients with selected rare cancer types (2018) (0)
- 1168PEstimation of benefice to anti-PD-(L)1 for metastatic patients by real-time quantitative and functional estimation of immune infiltrate with RNAseq (2017) (0)
- Immune Contexture of Pediatric Cancers (2022) (0)
- Use of the Pallia 10 score in patients enrolled in phase I trials at Gustave Roussy Cancer Center. (2021) (0)
- Immunotherapy for Pediatric Malignancies (2017) (0)
- Abstract CT069: A Phase I study of the oncolytic peptide LTX-315 generatesde novoT-cell responses and clinical benefit in patients with advanced melanoma (2019) (0)
- 20P Human virome epitope-level antiviral antibody profiling identified the cytomegalovirus (CMV) as the main driver of senescent immune phenotype (SIP) in patients with advanced non-small cell lung cancer (aNSCLC) (2022) (0)
- Targeting B-Cell Lymphoma with Idiotype-Specific Peptibodies: Toward a Personalized and Tumor-Specific Therapy (2012) (0)
- Neurological Complications Induced by Anti-PD-1 or Anti-PD-L1: Prevalence, Clinical Description and Treatment: 5-Years Experience of a National Network (2019) (0)
- Local Treg Immunomodulation Cures Metastatic Lymphoma Including CNS Sites (2011) (0)
- Molecular screening in advanced cancer patients with head and neck cancers: A retrospective analysis of the MOSCATO-01 trial. (2018) (0)
- 1632PDA novel radiomic based imaging tool to monitor tumor lymphocyte infiltration and outcome of patients treated by anti-PD-1/PD-L1 (2017) (0)
- Predictors of responses to immune checkpoint blockade in advanced melanoma (2017) (0)
- 315 W0180 novel anti-VISTA antibody: Rationale for target patient population and first-in-human trial design in monotherapy and in combination with anti-PD1 antibody (2020) (0)
- The polarity and specificity of SARS-CoV2 -specific T lymphocyte responses determine disease susceptibility (2021) (0)
- Promotes Tumor Growth and Metastasis by Modulating the Functions of T Regulatory andMyeloid-Derived Suppressor Cells (2015) (0)
- Methods to study mitochondrial DNA damage (2018) (0)
- Abstract 1251: Low plasma Arginine level is associated with resistance to immune checkpoint blockers in patients with advanced cancer (2022) (0)
- SAFETY PROFILE OF COMBINATION THERAPY WITH IMMUNE CHECKPOINT BLOCKERS AND VEGF INHIBITORS IN OLDER PATIENTS TREATED IN EARLY PHASE CLINICAL TRIALS (2019) (0)
- 984P Phase I dose escalation trial of nintedanib in combination with pembrolizumab in patients with advanced solid tumors (PEMBIB trial) (2021) (0)
- Abstract CT141: Safety and efficacy results from a phase I dose-escalation trial of Nintedanib in combination with Pembrolizumab in patients with advanced solid tumors (PEMBIB trial) (2018) (0)
- Profile and Outcome of Cancer Patients enrolled in Contemporary Phase I Trials (2023) (0)
- Abstract 1109: The antimicrobial peptide LL37 activates plasmacytoid dendritic cells in breast cancer (2014) (0)
- 797P Health-related quality of life (HRQoL) with pembrolizumab (pembro) monotherapy in patients (pts) with previously treated advanced microsatellite instability high (MSI-H) endometrial cancer: Results from KEYNOTE-158 (2021) (0)
- 41P BRCA2 pathogenic variant (PV): A novel agnostic biomarker for immune checkpoint blockers (ICB)? (2023) (0)
- P012 Patients with cancer and preexisting autoimmune and inflammatory diseases treated by anti-programmed death 1 (PD-1) antibodies at gustave roussy cancer center (2019) (0)
- Phaco Cypass (2018) (0)
- Abstract A027: Clonal hematopoiesis of indeterminate potential (CHIP) in patients with advanced NSCLC treated with immune checkpoint blockers (ICB) as monotherapy: Analysis of the PREMIS study. [R] (2023) (0)
- Abstract 2326: LTX-315, an oncolytic peptide, increases anticancer immunity mediated by CTLA4 blockade in an interleukin-2 receptor beta-chain-dependent manner (2016) (0)
- DRES-08. CLINICAL SIGNIFICANCE OF HYPERMUTATION IN GLIOMAS (2019) (0)
- Immunological Cytopenias Induced By Anti-Programmed Cell Death (ligand) 1 Antibodies (2018) (0)
- 1773P Anti-PD1-induced acute interstitial pneumonitis is characterized by alveolar infiltration of PD-1+CD38+TIGIT+ cytotoxic effector CD8+ T cells and CD206+ inflammatory macrophages (2021) (0)
- PALLIA 10 score in phase I cancer studies (2022) (0)
- Immune-related generalised oedema - A new category of adverse events with immune checkpoint inhibitors. (2022) (0)
- Stromal lymphocyte infiltration is associated with tumor invasion depth but is not prognostic in high-grade T1 bladder cancer (2018) (0)
- Sustained Type I interferon signaling as a mechanism of resistance to PD-1 blockade (2019) (0)
- 1286P Senescent immune phenotype (SIP) status predicts resistance to immune checkpoint blockers (ICB) among CMV+ advanced non-small cell lung cancer (aNSCLC) patients (2021) (0)
- 502 Recommended phase 2 dose, pharmacokinetics, pharmacodynamics, and preliminary efficacy of the IL-15 superagonist SO-C101 as monotherapy in patients with advanced/metastatic solid tumors (2021) (0)
- 901 Bacillus Calmette-Guerin can subvert patients antitumor immune response by downregulating HLA-I expression on cancer cells (2021) (0)
- Evaluating immunotherapy-related adverse events reporting in the French national hospital discharge database (PMSI): a pilot study (2023) (0)
- Effect of CD137 stimulation on ibrutinib antagonism of GA101 dependent NK cell-mediated cytotoxicity. (2015) (0)
- Abstract 5128: Induction of immunogenic cell death and tumor regression in murine animal models by a novel cytolytic compound, LTX-401 (2017) (0)
- Prognostic value of tumor immune biomarkers in biopsies from patients with refractory solid cancers. (2022) (0)
- 1694P Discovery of circulating biomarkers in COVID-19 patients undergoing anti-IL6R immunotherapy (2020) (0)
- 1109TiPMEDINDUCTION: Phase I trial evaluating the safety of durvalumab in combination with Docetaxel, Cisplatin and 5-FU (DCF) in induction for locally advanced squamous cell carcinoma of the head and neck (SCCHN) (2017) (0)
- SP-0258: Potentiation of anti-tumor immune effects by PARP Inhibitors (2020) (0)
- Author Correction: The immuno-oncological challenge of COVID-19 (2022) (0)
- Abstract CT179: First-in-human study of ICT01, an anti-BTN3A activating monoclonal antibody in combination with low dose IL-2 in patients with advanced solid tumors (EVICTION-2 study) (2023) (0)
- Abstract P2-13-02: COBRA: Characteristics and Outcomes of patients with BReast cancer in phAse I trials at Gustave Roussy Cancer center (2023) (0)
- 732MO The combination of ICT01, a γ9δ2 T cell-activating mAb, plus pembrolizumab induces a broad antitumor immune response and disease control in patients with CPI-failure melanoma, NSCLC and bladder cancer: EVICTION trial (2022) (0)
- 47P Radiological patterns of tumour progression in patients treated with a combination of immune checkpoint blockers and antiangiogenic drugs (2020) (0)
- 958O Coordinated activation of antitumor responses of g9d2 and CD8 T-cells by targeting BTN3A with ICT01 in patients with solid tumors: EVICTION trial (2021) (0)
- Precision medicine for patients with rare cancers: An effective strategy within the prospective MOSCATO trial. (2018) (0)
- A novel phase I/IIa open-label study of IMM-101 in combination with selected standard of care regimens in patients with metastatic cancer or unresectable cancer at study entry. (2017) (0)
- Abstract A14: Overcoming therapeutic MAb resistance in agressive HER2 positive breast carcinomas by adoptive immunotherapy using optizimed effectors cells (2015) (0)
- Abstract LB-139: In situ Treg immunomodulation at a single tumor site with CpG and immune checkpoint antibodies cures metastatic disease (2012) (0)
- 503 Clinical activity of ICT01, an anti-BTN3A-targeted, γ9δ2-activating mAb, alone and in combination with pembrolizumab in patients with advanced/refractory solid tumors: EVICTION trial (2021) (0)
- 1171PCheckpoint inhibitors in MSI tumors: Lessons from a monocentric experience (2017) (0)
- Rapid and objective CT-scan prognostic scoring identifies patients with long-term clinical benefit on phase I trials (2016) (0)
- 1732MO Pembrolizumab and nintedanib for patients with advanced mesothelioma (2021) (0)
- The Tetraspanin CD81 Facilitates Tumor Metastasis By Modulating Immune Suppression (2014) (0)
- Abstract 1011: RNAseq analysis obtained from on-purpose tumor biopsies of patients in the MATCH-R trial allows the identification of potential mechanisms of acquired resistance to PD(L)1 therapies (2017) (0)
- Neo-Adjuvant immunotherapies: Bladder cancer as a platform for drug development targeting mucosal immunity. (2023) (0)
- 113P Pembrolizumab in microsatellite instability-high (MSI-H)/mismatch repair deficient (dMMR) advanced solid tumors: An update of the phase II KEYNOTE-158 trial (2022) (0)
- Abstract 1993: Biomarker analyses from the Phase I clinical trial of the first-in-class SIRPa immune checkpoint inhibitor BI765063 in patients with advanced solid tumors (2022) (0)
- Relapsed and refractory classical Hodgkin lymphoma: could virotherapy help solve the equation? (2021) (0)
- 472P Prognostic markers in patients (pts) with solid tumors submitted to bispecific T-cell engagers in phase I (phI) clinical trials (2022) (0)
- 378 Efficacy, safety and ancillary analyses of pembrolizumab in combination with nintedanib for the treatment of patients with relapsed advanced mesothelioma (2021) (0)
- Melanoma and immunotherapy bridge 2015 (2016) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Aurélien Marabelle?
Aurélien Marabelle is affiliated with the following schools:
